← Back to Clinical Trials
Recruiting Phase 3 NCT06456489

NCT06456489 Pulse Steroid Injection in Refractory Rheumatoid Arthritis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06456489
Status Recruiting
Phase Phase 3
Sponsor Sohag University
Condition Active Rheumatoid Arthritis
Study Type INTERVENTIONAL
Enrollment 268 participants
Start Date 2024-05-01
Primary Completion 2024-09-30

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Solumedrol

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.

This trial targets 268 participants in total. It began in 2024-05-01 with a primary completion date of 2024-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Remission or low disease activity in active rheumatoid arthritis

Eligibility Criteria

Inclusion Criteria: * Refractory rheumatoid arthritis patients Exclusion Criteria: * Other connective tissue diseases * Endocrine diseases such as DM and thyroid disorders

Frequently Asked Questions

Who can join the NCT06456489 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 65 Years, studying Active Rheumatoid Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06456489 trial and what does that mean for participants?

Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 268 participants.

Is NCT06456489 currently recruiting?

Yes, NCT06456489 is actively recruiting participants. Visit ClinicalTrials.gov or contact Sohag University to inquire about joining.

Where is the NCT06456489 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT06456489 clinical trial?

NCT06456489 is sponsored by Sohag University. The trial plans to enroll 268 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology